Transfer of Treasury Shares

Venture Life Group PLC

06 October 2026

 

6 October 2026

VENTURE LIFE GROUP PLC

("Venture Life", "VLG" or the "Group")

Transfer of Treasury Shares

Venture Life Group PLC (AIM: VLG), a leader in product innovation, development and commercialisation within the global consumer healthcare sector, announces that today the Company transferred 110,000 ordinary shares of 0.3p each in the Company (“Ordinary Shares”) out of treasury to settle options exercised by an employee in accordance with the Company’s employee share option scheme.

Following the transfer, the total number of Ordinary Shares in issue will be 128,860,145, with 10,133,387 Ordinary Shares held in treasury. Therefore, the total number of voting rights will be 118,726,758. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.

For further information, please contact:

Venture Life Group PLC                                                                           [phone]

Jerry Randall, Chief Executive Officer

Daniel Wells, Chief Financial Officer

Cavendish Capital Markets Limited (Nomad and Broker)                           [phone] 

Stephen Keys/George Lawson (Corporate Finance)

Michael Johnson (Sales) 

About Venture Life (www.venture-life.com)

Venture Life is a growing pure-play consumer healthcare company focused on the specific market opportunity of Proactive Healthy Longevity. The company has a core portfolio, its Power Brands, of high growth, high margin products that promote and support consumer's goals of maintaining health and longevity. The Power Brands include Balance Activ in women's intimate healthcare, Earol® supporting ENT care, Lift and Glucogel product ranges for energy and glucose management and hypoglycaemia, the Health and Her product range supporting the hormonal lifecycle, and the FemiClear products which address a range of common women’s intimate health conditions.

These products, which are typically recommended by pharmacists or healthcare practitioners, are available primarily through health & beauty stores, pharmacies, grocery multiples and e-commerce channels. Venture Life has direct distribution in the UK, Ireland and the USA, supplying products directly to retailer partners and supporting these products in-market. Outside of these territories Venture Life uses international distribution partners to sell its products, with those partners being responsible for the support and distribution of the products in-market

 

END